Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $3.5
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital analyst Edward Woo maintains a Buy rating on IGC Pharma (AMEX:IGC) and raises the price target from $3.25 to $3.5.
July 29, 2024 | 10:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendiant Capital analyst Edward Woo maintains a Buy rating on IGC Pharma and raises the price target from $3.25 to $3.5.
The raised price target and maintained Buy rating from Ascendiant Capital are positive signals for IGC Pharma, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100